Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock

Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawal, H. A., Kocheril, A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976952/
https://www.ncbi.nlm.nih.gov/pubmed/29862089
http://dx.doi.org/10.1155/2018/8231576
_version_ 1783327269877448704
author Rawal, H. A.
Kocheril, A. G.
author_facet Rawal, H. A.
Kocheril, A. G.
author_sort Rawal, H. A.
collection PubMed
description Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was started on this new medication. On sacubitril/valsartan, he developed cardiogenic shock. This led us to reevaluate the use and risks of this medication in the class IV heart failure population.
format Online
Article
Text
id pubmed-5976952
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59769522018-06-03 Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock Rawal, H. A. Kocheril, A. G. Case Rep Cardiol Case Report Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was started on this new medication. On sacubitril/valsartan, he developed cardiogenic shock. This led us to reevaluate the use and risks of this medication in the class IV heart failure population. Hindawi 2018-05-15 /pmc/articles/PMC5976952/ /pubmed/29862089 http://dx.doi.org/10.1155/2018/8231576 Text en Copyright © 2018 H. A. Rawal and A. G. Kocheril. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Rawal, H. A.
Kocheril, A. G.
Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
title Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
title_full Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
title_fullStr Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
title_full_unstemmed Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
title_short Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
title_sort sacubitril/valsartanstive heart failure: cardiogenic shock
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976952/
https://www.ncbi.nlm.nih.gov/pubmed/29862089
http://dx.doi.org/10.1155/2018/8231576
work_keys_str_mv AT rawalha sacubitrilvalsartanstiveheartfailurecardiogenicshock
AT kocherilag sacubitrilvalsartanstiveheartfailurecardiogenicshock

Ejemplares similares